About this item:
290 Views | 186 Downloads
Author Notes:
Raymond F. Schinazi PhD, DSc, Center for AIDS Research, Emory University School of Medicine, Atlanta, GA,USA. rschina@emory.edu.
Raymond Schinazi is the founder and major shareholder of Cocrystal Pharma, Inc.
Tarik Asselah is a speaker and investigator for BMS, Janssen, Gilead, Roche and Merck.
Maryam Ehteshami and Leda Bassit have no conflicts of interest to declare.
Subjects:
Research Funding:
This work was supported by NIH grant 1R01-AI-132833; and in part by funding from the NIH funded Emory Center for AIDS Research grant P30-AI-050409 to RFS.
Keywords:
- Science & Technology
- Life Sciences & Biomedicine
- Gastroenterology & Hepatology
- antiviral agents
- cccDNA
- HBV cure
- immunotherapy
- HEPATITIS-B-VIRUS
- INHIBITOR MYRCLUDEX-B
- ANTIGEN-POSITIVE PATIENTS
- IN-VIVO
- TENOFOVIR ALAFENAMIDE
- HBSAG QUANTIFICATION
- EFFECTOR NUCLEASES
- NATURAL-HISTORY
- AGONIST GS-9620
- INFECTION
Towards HBV curative therapies
Abstract:
Tremendous progress has been made over the last 2 decades to discover and develop approaches to control hepatitis B virus (HBV) infections and to prevent the development of hepatocellular carcinoma using various interferons and small molecules as antiviral agents. However, none of these agents have significant impact on eliminating HBV from infected cells. Currently the emphasis is on silencing or eliminating cccDNA, which could lead to a cure for HBV. Various approaches are being developed including the development of capsid effectors, CRISPR/Cas9, TALENS, siRNA, entry and secretion inhibitors, as well as immunological approaches. It is very likely that a combination of these modalities will need to be employed to successfully eliminate HBV or prevent virus rebound on discontinuation of therapy. In the next 5 years clinical data will emerge which will provide insight on the safety and feasibility of these approaches and if they can be applied to eradicate HBV infections globally. In this review, we summarize current treatments and we highlight and examine recent therapeutic strategies that are currently being evaluated at the preclinical and clinical stage.
Copyright information:
© 2018 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd
This is an Open Access work distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (http://creativecommons.org/licenses/by-nc-nd/4.0/).
